Qi Peng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Qi Peng has a total of 103 co-authors. Here are the top co-authors by number of shared publications:
- Chuan-Yun Li
State Key Laboratory of Protein and Plant Gene Research, Laboratory of Bioinformatics and Genomic Medicine, Institute of Molecular Medicine, College of Future Technology, Peking University , Beijing 100080
5 shared publications - Mingchun Li
National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, College of Life Sciences, Nankai University, Tianjin 300071, China
3 shared publications - Qilin Yu
National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, College of Life Sciences, Nankai University, Tianjin 300071, China
3 shared publications - Wanqiu Ding
Beijing Key Laboratory of Cardiometabolic Molecular Medicine, Institute of Molecular Medicine, College of Future Technology, Peking University
3 shared publications - Ying Liu
State Key Laboratory of Membrane Biology, New Cornerstone Science Laboratory, College of Future Technology, Peking University, Beijing, China.
3 shared publications - Bing Zhang
Key Laboratory of Molecular Microbiology and Technology, Ministry of Education, Department of Microbiology, College of Life Science, Nankai University, Tianjin, 300071, People's Republic of China
2 shared publications
Latest Publications
- Open Access
- 22 June 2026
- Published by Springer Nature in Cell Death & Disease
- Vol. 17 (1)
Combined inhibition of BETs and HDACs as a potential epigenetics-based therapy for malignant rhabdoid tumor
Malignant rhabdoid tumors (MRT) are highly aggressive pediatric malignancies driven by SMARCB1 loss and consequent epigenetic dysregulation, with dismal survival rates underscoring the need for novel therapies. Given the central role of chromatin modifiers in MRT pathogenesis, we investigated a novel combinatorial epigenetic approach simultaneously targeting histone deacetylases (HDACs) and bromodomain and extraterminal (BET) family proteins. Using a focused epigenetic compound screen across multiple MRT cell lines, we identified that the HDAC inhibitor panobinostat (LBH589) and the BET inhibitor birabresib (OTX015) act synergistically to inhibit cell proliferation, with combination index (CI) values consistently <1. Transcriptomic profiling revealed that this synergy is underpinned by a profound downregulation of cell cycle genes, leading to G1/S phase arrest. Mechanistically, the combination therapy cooperatively restores the expression of the cyclin-dependent kinase inhibitors p21 and p16. This restoration inhibits cyclin D1–CDK4/6 kinase activity, reduces retinoblastoma protein (Rb) phosphorylation, and consequently represses the E2F1 transcriptional program and its key targets, including cyclin A2 and cyclin B1. In vivo, this dual-epigenetic targeting significantly attenuated tumor growth in MRT xenograft models, outperforming either monotherapy, and was associated with suppressed proliferation and E2F1 signaling. Our findings unveil a novel synergistic strategy that pharmacologically recapitulates a core SMARCB1-mediated tumor-suppressive circuit, nominating combined HDAC and BET inhibition as a promising therapeutic avenue for MRT.
- 22 June 2026
- Published by Springer Nature in Cell Death & Disease
- Vol. 17 (1)
Open AccessCombined inhibition of BETs and HDACs as a potential epigenetics-based therapy for malignant rhabdoid tumor
Malignant rhabdoid tumors (MRT) are highly aggressive pediatric malignancies driven by SMARCB1 loss and consequent epigenetic dysregulation, with dismal survival rates underscoring the need for novel therapies. Given the central role of chromatin modifiers in MRT pathogenesis, we investigated a novel combinatorial epigenetic approach simultaneously targeting histone deacetylases (HDACs) and bromodomain and extraterminal (BET) family proteins. Using a focused epigenetic compound screen across multiple MRT cell lines, we identified that the HDAC inhibitor panobinostat (LBH589) and the BET inhibitor birabresib (OTX015) act synergistically to inhibit cell proliferation, with combination index (CI) values consistently <1. Transcriptomic profiling revealed that this synergy is underpinned by a profound downregulation of cell cycle genes, leading to G1/S phase arrest. Mechanistically, the combination therapy cooperatively restores the expression of the cyclin-dependent kinase inhibitors p21 and p16. This restoration inhibits cyclin D1–CDK4/6 kinase activity, reduces retinoblastoma protein (Rb) phosphorylation, and consequently represses the E2F1 transcriptional program and its key targets, including cyclin A2 and cyclin B1. In vivo, this dual-epigenetic targeting significantly attenuated tumor growth in MRT xenograft models, outperforming either monotherapy, and was associated with suppressed proliferation and E2F1 signaling. Our findings unveil a novel synergistic strategy that pharmacologically recapitulates a core SMARCB1-mediated tumor-suppressive circuit, nominating combined HDAC and BET inhibition as a promising therapeutic avenue for MRT.
- Open Access
- 29 January 2026
- Published by Springer Nature in Research Square
Combined inhibition of BETs and HDACs as a potential epigenetics-based therapy for malignant rhabdoid tumor
Malignant rhabdoid tumors (MRT) are highly aggressive pediatric malignancies driven by SMARCB1 loss and consequent epigenetic dysregulation, with dismal survival rates underscoring the need for novel therapies. Given the central role of chromatin modifiers in MRT pathogenesis, we investigated a novel combinatorial epigenetic approach simultaneously targeting histone deacetylases (HDACs) and bromodomain and extraterminal (BET) family proteins. Using a focused epigenetic compound screen across multiple MRT cell lines, we identified that the HDAC inhibitor panobinostat (LBH589) and the BET inhibitor birabresib (OTX015) act synergistically to inhibit cell proliferation, with combination index (CI) values consistently < 1. Transcriptomic profiling revealed that this synergy is underpinned by a profound downregulation of cell cycle genes, leading to G₁/S phase arrest. Mechanistically, the combination therapy cooperatively restores the expression of the cyclin-dependent kinase inhibitors CDKN1A and CDKN2A. This restoration inhibits cyclin D1–CDK4/6 kinase activity, reduces RB protein phosphorylation, and consequently represses the E2F1 transcriptional program and its key targets, including cyclin A2 and cyclin B1. In vivo , this dual-epigenetic targeting significantly attenuated tumor growth in MRT xenograft models, outperforming either monotherapy, and was associated with suppressed proliferation and E2F1 signaling. Our findings unveil a novel synergistic strategy that pharmacologically recapitulates a core SMARCB1-mediated tumor-suppressive circuit, nominating combined HDAC and BET inhibition as a promising therapeutic avenue for MRT.
- 29 January 2026
- Published by Springer Nature in Research Square
Open AccessCombined inhibition of BETs and HDACs as a potential epigenetics-based therapy for malignant rhabdoid tumor
Malignant rhabdoid tumors (MRT) are highly aggressive pediatric malignancies driven by SMARCB1 loss and consequent epigenetic dysregulation, with dismal survival rates underscoring the need for novel therapies. Given the central role of chromatin modifiers in MRT pathogenesis, we investigated a novel combinatorial epigenetic approach simultaneously targeting histone deacetylases (HDACs) and bromodomain and extraterminal (BET) family proteins. Using a focused epigenetic compound screen across multiple MRT cell lines, we identified that the HDAC inhibitor panobinostat (LBH589) and the BET inhibitor birabresib (OTX015) act synergistically to inhibit cell proliferation, with combination index (CI) values consistently < 1. Transcriptomic profiling revealed that this synergy is underpinned by a profound downregulation of cell cycle genes, leading to G₁/S phase arrest. Mechanistically, the combination therapy cooperatively restores the expression of the cyclin-dependent kinase inhibitors CDKN1A and CDKN2A. This restoration inhibits cyclin D1–CDK4/6 kinase activity, reduces RB protein phosphorylation, and consequently represses the E2F1 transcriptional program and its key targets, including cyclin A2 and cyclin B1. In vivo , this dual-epigenetic targeting significantly attenuated tumor growth in MRT xenograft models, outperforming either monotherapy, and was associated with suppressed proliferation and E2F1 signaling. Our findings unveil a novel synergistic strategy that pharmacologically recapitulates a core SMARCB1-mediated tumor-suppressive circuit, nominating combined HDAC and BET inhibition as a promising therapeutic avenue for MRT.
- Open Access
- 5 April 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (14) , eadl4600
Adaptive functions of structural variants in human brain development
Quantifying the structural variants (SVs) in nonhuman primates could provide a niche to clarify the genetic backgrounds underlying human-specific traits, but such resource is largely lacking. Here, we report an accurate SV map in a population of 562 rhesus macaques, verified by in-house benchmarks of eight macaque genomes with long-read sequencing and another one with genome assembly. This map indicates stronger selective constrains on inversions at regulatory regions, suggesting a strategy for prioritizing them with the most important functions. Accordingly, we identified 75 human-specific inversions and prioritized them. The top-ranked inversions have substantially shaped the human transcriptome, through their dual effects of reconfiguring the ancestral genomic architecture and introducing regional mutation hotspots at the inverted regions. As a proof of concept, we linked APCDD1 , located on one of these inversions and down-regulated specifically in humans, to neuronal maturation and cognitive ability. We thus highlight inversions in shaping the human uniqueness in brain development.
- 5 April 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (14) , eadl4600
Open AccessAdaptive functions of structural variants in human brain development
Quantifying the structural variants (SVs) in nonhuman primates could provide a niche to clarify the genetic backgrounds underlying human-specific traits, but such resource is largely lacking. Here, we report an accurate SV map in a population of 562 rhesus macaques, verified by in-house benchmarks of eight macaque genomes with long-read sequencing and another one with genome assembly. This map indicates stronger selective constrains on inversions at regulatory regions, suggesting a strategy for prioritizing them with the most important functions. Accordingly, we identified 75 human-specific inversions and prioritized them. The top-ranked inversions have substantially shaped the human transcriptome, through their dual effects of reconfiguring the ancestral genomic architecture and introducing regional mutation hotspots at the inverted regions. As a proof of concept, we linked APCDD1 , located on one of these inversions and down-regulated specifically in humans, to neuronal maturation and cognitive ability. We thus highlight inversions in shaping the human uniqueness in brain development.
- Open Access
- 20 October 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 9 (42) , eadh7912
6mA-Sniper: Quantifying 6mA sites in eukaryotes at single-nucleotide resolution
While N 6 -methyldeoxyadenine (6mA) modification is a fundamental regulation in prokaryotes, its prevalence and functions in eukaryotes are controversial. Here, we report 6mA-Sniper to quantify 6mA sites in eukaryotes at single-nucleotide resolution, and delineate a 6mA profile in Caenorhabditis elegans with 2034 sites. Twenty-six of 39 events with Mnl I restriction endonuclease sites were verified, demonstrating the feasibility of this method. The levels of 6mA sites pinpointed by 6mA-Sniper are generally increased after Pseudomonas aeruginosa infection, but decreased in strains with the removal of METL-9, the dominant 6mA methyltransferase. The enrichment of these sites on specific motif of [GC]G A G, the selective constrains on them, and their coordinated changes with METL-9 levels thus support an active shaping of the 6mA profile by methyltransferase. Moreover, for regions marked by 6mA sites that emerged after infection, an enrichment of up-regulated genes was detected, possibly mediated through a mutual exclusive cross-talk between 6mA and H3K27me3 modification. We thus highlight 6mA regulation as a previously neglected regulator in eukaryotes.
- 20 October 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 9 (42) , eadh7912
Open Access6mA-Sniper: Quantifying 6mA sites in eukaryotes at single-nucleotide resolution
While N 6 -methyldeoxyadenine (6mA) modification is a fundamental regulation in prokaryotes, its prevalence and functions in eukaryotes are controversial. Here, we report 6mA-Sniper to quantify 6mA sites in eukaryotes at single-nucleotide resolution, and delineate a 6mA profile in Caenorhabditis elegans with 2034 sites. Twenty-six of 39 events with Mnl I restriction endonuclease sites were verified, demonstrating the feasibility of this method. The levels of 6mA sites pinpointed by 6mA-Sniper are generally increased after Pseudomonas aeruginosa infection, but decreased in strains with the removal of METL-9, the dominant 6mA methyltransferase. The enrichment of these sites on specific motif of [GC]G A G, the selective constrains on them, and their coordinated changes with METL-9 levels thus support an active shaping of the 6mA profile by methyltransferase. Moreover, for regions marked by 6mA sites that emerged after infection, an enrichment of up-regulated genes was detected, possibly mediated through a mutual exclusive cross-talk between 6mA and H3K27me3 modification. We thus highlight 6mA regulation as a previously neglected regulator in eukaryotes.
- Open Access
- 11 September 2023
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 13, 1282120
Corrigendum: Systematic characterization of the clinical relevance of KPNA4 in pancreatic ductal adenocarcinoma
Corrigendum: Systematic characterization of the clinical relevance of KPNA4 in pancreatic ductal adenocarcinoma
- 11 September 2023
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 13, 1282120
Open AccessCorrigendum: Systematic characterization of the clinical relevance of KPNA4 in pancreatic ductal adenocarcinoma
Corrigendum: Systematic characterization of the clinical relevance of KPNA4 in pancreatic ductal adenocarcinoma
- Open Access
- 5 June 2023
- Published by Springer Nature in Cell Research
- Vol. 33 (8) , 628-639
A novel N6-Deoxyadenine methyltransferase METL-9 modulates C. elegans immunity via dichotomous mechanisms
N6-Methyldeoxyadenine (6mA) has been rediscovered as a DNA modification with potential biological function in metazoans. However, the physiological function and regulatory mechanisms regarding the establishment, maintenance and removal of 6mA in eukaryotes are still poorly understood. Here we show that genomic 6mA levels change in response to pathogenic infection in Caenorhabditis elegans (C. elegans). We further identify METL-9 as the methyltransferase that catalyzes DNA 6mA modifications upon pathogen infection. Deficiency of METL-9 impairs the induction of innate immune response genes and renders the animals more susceptible to pathogen infection. Interestingly, METL-9 functions through both 6mA-dependent and -independent mechanisms to transcriptionally regulate innate immunity. Our findings reveal that 6mA is a functional DNA modification in immunomodulation in C. elegans.
- 5 June 2023
- Published by Springer Nature in Cell Research
- Vol. 33 (8) , 628-639
Open AccessA novel N6-Deoxyadenine methyltransferase METL-9 modulates C. elegans immunity via dichotomous mechanisms
N6-Methyldeoxyadenine (6mA) has been rediscovered as a DNA modification with potential biological function in metazoans. However, the physiological function and regulatory mechanisms regarding the establishment, maintenance and removal of 6mA in eukaryotes are still poorly understood. Here we show that genomic 6mA levels change in response to pathogenic infection in Caenorhabditis elegans (C. elegans). We further identify METL-9 as the methyltransferase that catalyzes DNA 6mA modifications upon pathogen infection. Deficiency of METL-9 impairs the induction of innate immune response genes and renders the animals more susceptible to pathogen infection. Interestingly, METL-9 functions through both 6mA-dependent and -independent mechanisms to transcriptionally regulate innate immunity. Our findings reveal that 6mA is a functional DNA modification in immunomodulation in C. elegans.
- Open Access
- 15 September 2020
- Published by Springer Nature in Nature Communications
- Vol. 11 (1) , 1-12
Histone deacetylase HDA-1 modulates mitochondrial stress response and longevity
The ability to detect, respond and adapt to mitochondrial stress ensures the development and survival of organisms. Caenorhabditis elegans responds to mitochondrial stress by activating the mitochondrial unfolded protein response (UPRmt) to buffer the mitochondrial folding environment, rewire the metabolic state, and promote innate immunity and lifespan extension. Here we show that HDA-1, the C. elegans ortholog of mammalian histone deacetylase (HDAC) is required for mitochondrial stress-mediated activation of UPRmt. HDA-1 interacts and coordinates with the genome organizer DVE-1 to induce the transcription of a broad spectrum of UPRmt, innate immune response and metabolic reprogramming genes. In rhesus monkey and human tissues, HDAC1/2 transcript levels correlate with the expression of UPRmt genes. Knocking down or pharmacological inhibition of HDAC1/2 disrupts the activation of the UPRmt and the mitochondrial network in mammalian cells. Our results underscore an evolutionarily conserved mechanism of HDAC1/2 in modulating mitochondrial homeostasis and regulating longevity.
- 15 September 2020
- Published by Springer Nature in Nature Communications
- Vol. 11 (1) , 1-12
Open AccessHistone deacetylase HDA-1 modulates mitochondrial stress response and longevity
The ability to detect, respond and adapt to mitochondrial stress ensures the development and survival of organisms. Caenorhabditis elegans responds to mitochondrial stress by activating the mitochondrial unfolded protein response (UPRmt) to buffer the mitochondrial folding environment, rewire the metabolic state, and promote innate immunity and lifespan extension. Here we show that HDA-1, the C. elegans ortholog of mammalian histone deacetylase (HDAC) is required for mitochondrial stress-mediated activation of UPRmt. HDA-1 interacts and coordinates with the genome organizer DVE-1 to induce the transcription of a broad spectrum of UPRmt, innate immune response and metabolic reprogramming genes. In rhesus monkey and human tissues, HDAC1/2 transcript levels correlate with the expression of UPRmt genes. Knocking down or pharmacological inhibition of HDAC1/2 disrupts the activation of the UPRmt and the mitochondrial network in mammalian cells. Our results underscore an evolutionarily conserved mechanism of HDAC1/2 in modulating mitochondrial homeostasis and regulating longevity.
- Open Access
- 12 March 2020
- Published by Springer Nature in Cell Death & Disease
- Vol. 11 (3) , 1-14
Prohibitin 2 deficiency impairs cardiac fatty acid oxidation and causes heart failure
Fatty acids are the most major substrate source for adult cardiac energy generation. Prohibitin 2 (PHB2), a highly conserved protein located in mitochondrial inner membrane, plays key roles in cellular energy metabolic homeostasis. However, its functions in regulating cardiac fatty acid metabolism have remained largely unknown. Our study demonstrates that cardiac-specific knockout of Phb2 leads to accumulation of lipid droplets and causes heart failure. Mechanistically, ablation of PHB2 impairs cardiac fatty acid oxidation (FAO) through downregulating carnitine palmitoyltransferase1b (CPT1b), a rate-limiting enzyme of cardiac mitochondrial FAO. Moreover, overexpression of CPT1b alleviates impaired FAO in PHB2-deficient cardiomyocytes. Thus, our study provides direct evidence for the link between PHB2 and cardiac fatty acid metabolism. Our study points out that PHB2 is a potential FAO regulator in cardiac mitochondrial inner membrane, as well as the connection between PHB2 and CPT1b and their relationships to cardiac pathology especially to cardiac fatty acid metabolic disorder.
- 12 March 2020
- Published by Springer Nature in Cell Death & Disease
- Vol. 11 (3) , 1-14
Open AccessProhibitin 2 deficiency impairs cardiac fatty acid oxidation and causes heart failure
Fatty acids are the most major substrate source for adult cardiac energy generation. Prohibitin 2 (PHB2), a highly conserved protein located in mitochondrial inner membrane, plays key roles in cellular energy metabolic homeostasis. However, its functions in regulating cardiac fatty acid metabolism have remained largely unknown. Our study demonstrates that cardiac-specific knockout of Phb2 leads to accumulation of lipid droplets and causes heart failure. Mechanistically, ablation of PHB2 impairs cardiac fatty acid oxidation (FAO) through downregulating carnitine palmitoyltransferase1b (CPT1b), a rate-limiting enzyme of cardiac mitochondrial FAO. Moreover, overexpression of CPT1b alleviates impaired FAO in PHB2-deficient cardiomyocytes. Thus, our study provides direct evidence for the link between PHB2 and cardiac fatty acid metabolism. Our study points out that PHB2 is a potential FAO regulator in cardiac mitochondrial inner membrane, as well as the connection between PHB2 and CPT1b and their relationships to cardiac pathology especially to cardiac fatty acid metabolic disorder.
- Open Access
- 13 August 2018
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 115 (35) , 8817-8822
Human exonization through differential nucleosome occupancy
Significance: Nucleosomal modifications have been implicated in fundamental epigenetic regulation, whereas the roles of nucleosome binding in shaping changes through evolution remain to be addressed. Here we performed a comparative study to clarify the roles of nucleosome occupancy in exon origination. By profiling a high-resolution, cross-species mononucleosome landscape for mammalian tissues, we found nucleosome occupancy profiles are conserved across tissues and species. Further, through a phylogenetic approach, we found that the feature of differential nucleosome occupancy appears prior to the origination of new exons and, presumably, facilitates the origin of new exons by increasing the splice strength of the ancestral nonexonic regions through driving a local difference in GC content, which suggests the function of nucleosome binding in exonization.
- 13 August 2018
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 115 (35) , 8817-8822
Open AccessHuman exonization through differential nucleosome occupancy
Significance: Nucleosomal modifications have been implicated in fundamental epigenetic regulation, whereas the roles of nucleosome binding in shaping changes through evolution remain to be addressed. Here we performed a comparative study to clarify the roles of nucleosome occupancy in exon origination. By profiling a high-resolution, cross-species mononucleosome landscape for mammalian tissues, we found nucleosome occupancy profiles are conserved across tissues and species. Further, through a phylogenetic approach, we found that the feature of differential nucleosome occupancy appears prior to the origination of new exons and, presumably, facilitates the origin of new exons by increasing the splice strength of the ancestral nonexonic regions through driving a local difference in GC content, which suggests the function of nucleosome binding in exonization.
- 6 August 2018
- Published by Wiley in Journal of Applied Toxicology
- Vol. 38 (12) , 1538-1544
Graphene oxide severely inhibits DNase activity
Graphene oxide (GO) is an important type of 2D nanomaterial and widely used in biomedicine, sensors, photocatalysis and electronic materials. With the extensive exposure of GO, its biological effect is debatable. In this study, we found a novel biological effect of GO, ie, suppression of deoxyribonuclease (DNase). GO inhibited DNA degradation when DNA or the DNA/RNA mixture was exposed to DNase. Moreover, GO suppressed nuclear fragmentation when the nuclei were treated with DNase. Interestingly, GO neither interacted with DNA nor influenced the interaction between DNase and DNA. Further investigation revealed that GO had a strong activity of adsorbing l‐phenylalanine and l‐histidine, key amino acid residues in the active site of DNase. These results suggest that GO could suppress the activity of DNase by interaction with the active site of DNase, and have an impact on DNase‐related cellular processes (eg, apoptosis), implying its potential application in treating diseases associated with disorderly DNase function.
- 6 August 2018
- Published by Wiley in Journal of Applied Toxicology
- Vol. 38 (12) , 1538-1544
Graphene oxide severely inhibits DNase activity
Graphene oxide (GO) is an important type of 2D nanomaterial and widely used in biomedicine, sensors, photocatalysis and electronic materials. With the extensive exposure of GO, its biological effect is debatable. In this study, we found a novel biological effect of GO, ie, suppression of deoxyribonuclease (DNase). GO inhibited DNA degradation when DNA or the DNA/RNA mixture was exposed to DNase. Moreover, GO suppressed nuclear fragmentation when the nuclei were treated with DNase. Interestingly, GO neither interacted with DNA nor influenced the interaction between DNase and DNA. Further investigation revealed that GO had a strong activity of adsorbing l‐phenylalanine and l‐histidine, key amino acid residues in the active site of DNase. These results suggest that GO could suppress the activity of DNase by interaction with the active site of DNase, and have an impact on DNase‐related cellular processes (eg, apoptosis), implying its potential application in treating diseases associated with disorderly DNase function.